SCHEMBL6436779

SCHEMBL6436779

CCOC(=O)N[C@@H](C(=O)O)C1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.44
ALDH1A1 P00352 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
THRB P10828 1/20 0.42
ATM Q13315 1/20 0.42
LMNA P02545 1/20 0.39
POLB P06746 2/20 0.39
KDM4E B2RXH2 1/20 0.39
PYGL P06737 4/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP3 P08254 1/20 0.38
MMP7 P09237 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14263864 1.00 TSHR (0.44) TSHRALDH1A1NPSR1L3MBTL1THRB
SCHEMBL6436784 1.00 TSHR (0.44) TSHRALDH1A1NPSR1L3MBTL1THRB
Hydrochloric Acid SCHEMBL27509412 0.98 TSHR (0.43) TSHRALDH1A1NPSR1L3MBTL1THRB
SCHEMBL10072215 0.87 ALDH1A1 (0.43) TSHRALDH1A1NPSR1L3MBTL1THRB
SCHEMBL10072210 0.86 ALDH1A1 (0.42) TSHRALDH1A1NPSR1L3MBTL1THRB
SCHEMBL4683301 0.85 HRH3 (0.42) TSHRPYGLGAAMAPTMMP1
SCHEMBL14401960 0.84 SMN1; SMN2 (0.40) ALDH1A1PYGLMMP1MMP2MMP3
SCHEMBL8505418 0.84 MMP1 (0.50) TSHRALDH1A1NPSR1L3MBTL1THRB
SCHEMBL10045004 0.84 ALDH1A1 (0.41) TSHRALDH1A1NPSR1L3MBTL1THRB
SCHEMBL8354667 0.84 SMN1; SMN2 (0.40) ALDH1A1PYGLMMP1MMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1505062-A1 Heterocyclic derivatives and their use as antithrombotic agents Akzo Nobel N.V. (NL) 2005-02-09 EP disclosed
US-6797710-B2 CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY AKZO NOBEL N.V. (NL) 2004-09-28 US disclosed
US-20030130270-A1 Heterocyclic derivatives and their use as antithrombotic agents MERCK SHARP & DOHME B.V. (NL) 2003-07-10 US disclosed
US-6444672-B1 ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR AKZO NOBEL N.V. (NL) 2002-09-03 US disclosed
US-6432955-B1 ANTICOAGULANTS AKZO NOBEL N.V. (NL) 2002-08-13 US disclosed
US-6194409-B1 SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH AKZO NOBEL N.V. (NL) 2001-02-27 US disclosed
EP-0975600-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS Akzo Nobel N.V. (NL) 2000-02-02 EP disclosed
WO-1998047876-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS AKZO NOBEL N.V. (NL) 1998-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130270-A1 Heterocyclic derivatives and their use as antithrombotic agents F2, F12, VKORC1 TSHR 3455/4885ALDH1A1 170/4885NPSR1 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.